We buy more and more drugs: Here's why

We buy more and more drugs: Here’s why

During 2022, the total amount of spending devoted to pharmaceutical procurement, including both state and private grants, reached 34.1 billion Euros, Shows an increase of 6.0% over the previous year. More than 60% of individuals, ie more than 60% of the population, have received at least one prescription. This figure was associated with an increase in per capita expenditure and drug consumption related to aging. Notably, persons over the age of 64 contributed mainly, absorbing more than 60% of the resources spent and units purchased.

It also emerges that the National Report of 2022 “drug use in italy“AIFA, prepared by the National Observatory for the Use of Medicines (Osmed), provides an overview of these data. This publication, now in its twenty-third edition, makes use of the resources provided by various information systems and in collaboration with various institutions. Its goal is to outline a comprehensive and analytical picture of the field of pharmaceutical assistance in Italy, both in the regional and hospital context. This includes both the responsibility of the National Health Service (SSN) and private purchases made by citizens.

more drugs are bought in the south

The public expenditure component, which amounts to 23.5 billion euros, has been formed 68.9% of the entire drug budget And 17.9% of public financial resources were allocated to health care. This figure saw an increase of 5.5% compared to 2021. Investments for the purchase of medicines by public health structures registered an increase of 8.6% compared to almost 15.0 billion euros (with an average of 253.6 euros per person). last year. The increase in spending paralleled the increase in consumption, which grew by 5.7%.

Northern regions show lower prevalence, equal to 63.1% compared to the central (68.4%) and southern (69.5%) regions. During 2022, 45.0% of the pediatric population received at least one drug prescription, with the percentage rising to 61.4% for pre-school children.

Compared to the previous year, there was an increase in the number of packs per person, mainly focused on children aged 6 to 11, although consumption was seen to increase across all age groups. Antimicrobials for systemic use and respiratory drugs remain the main types of drugs prescribed, both of which have seen significant increases in consumption.

Average cost for the elderly 556 Euro

in 2022 Per capita expenditure on medicines was 419.37 Euros.With an increase of 5.7% over the previous year, which includes receipts through public health structures and agreements. The consumption was 1325.21 DDD/1000 inhabitants per day, with an increase of 1.6% compared to 2021. The agreed assistance was 86% of the total dose.

The average expenditure in the old context was 556 Euro per person, distributed to 601.5 euros for men and 520.8 euros for women. The vast majority (98.4%) received at least one prescription drug during the year.

Among ATC Level I drug categories, the categories generating the most public expenditure showed an increase over the previous year. especially me Respiratory system and gastrointestinal system drugs And there is a significant increase in metabolism, probably due to the recent introduction of anti-diabetic drugs. These increases were mainly seen in public health facility purchases.

For the most commonly consumed drug categories, a significant increase was observed for drugs related to the central nervous system and blood and hematopoietic organs, especially in public health facilities. The increase in consumption of drugs for the blood and hematopoietic organs may be linked to the increased use of newer oral anticoagulants.

Most over-the-counter benzodiazepines and sex drugs

In 2022, the expenditure on class C drugs by citizens will reach approx. 6.5 billion euros, an increase of 6.9% over the previous year. Of this figure, 54% (equivalent to 3.5 billion Euros) is due to prescribed drugs, while the remaining 46% (equivalent to 2.99 billion Euros) is in relation to self-prescription drugs (SOP and OTC), including those sold in commercial establishments. Prescription drugs are also included.

Most cost-generating drug categories remain benzodiazepineI deterrents and for those erectile dysfunction, In self-medication drugs, the main active ingredients are ibuprofen and diclofenac.

In terms of conventions, cardiac drugs constitute the therapeutic category with the highest per capita expenditure (50.29 Euro) and highest consumption (487.4 DDD). For antineoplastic and immunomodulatory drugs as well as blood and hematopoietic organ drugs, the highest per capita expenditure (113.04 Euros, respectively) and highest consumption (53.0 DDD) were recorded among pharmaceuticals obtained directly from public facilities.

Among the different regions, Campania had the highest per capita gross expenditure on class A-SSN drugs, reaching 197.9 Euros per capita. In contrast, the lowest value was found in the autonomous province of Bolzano (115.3 euros per capita), with a difference of 71.6% between these two regions. As far as consumption is concerned, Campania ranks highest with 1,293.4 DDD/1,000 inhabitants per day, while the lowest consumption was found in the Autonomous Province of Bolzano (843.8 DDD/1,000 inhabitants per day).

Compared to other European countries, the incidence of drug expenditure is low in Italy.

In 2022, I off-patent drugs Category A contracted aid constituted the majority of expenditure and consumption (71.6% and 86.2%, respectively). Generic drugs, excluding drugs with patent coverage, represented 21.9% of spending and 30.3% of consumption.

In the biosimilar sector, consumption of older drugs has increased and positive trends have been observed for recently introduced drugs, such as anti-TNF-alpha, bevacizumab, rituximab, trastuzumab and teriparatide. However, regional variability in consumption and expenditure was noted.

The total expenditure on new medical institutions is increased from about 5,174 million Euros to about 8,540 million Euros in 2014 Euro in 2022. Expenditure related to orphan drugs, which includes purchases and subsidized care payments by public health facilities, is set to increase by 29.2% in 2022 compared to the previous year, reaching 1.98 billion euros. This figure represents 6.0% of NHS pharmaceutical expenditure.

Internationally, Italy has a lower incidence of spending on equivalent drugs than other European countries, but ranks first in the incidence of spending and consumption on biosimilar drugs. In terms of prices, taking into account both drugs distributed locally and in hospitals, Italy has higher prices than only France, Portugal and Poland. In terms of spending on orphan drugs, Italy ranks fifth after Austria, France, Belgium and Germany with 48.2 euros per capita. There has been an increase in expenditure in all these countries in the years 2021 and 2022.






Leave a Reply

Your email address will not be published. Required fields are marked *